GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InVivo Therapeutics Holdings Corp (OTCPK:NVIVQ) » Definitions » Equity-to-Asset

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Equity-to-Asset : 0.93 (As of Sep. 2023)


View and export this data going back to 2010. Start your Free Trial

What is InVivo Therapeutics Holdings Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. InVivo Therapeutics Holdings's Total Stockholders Equity for the quarter that ended in Sep. 2023 was $8.92 Mil. InVivo Therapeutics Holdings's Total Assets for the quarter that ended in Sep. 2023 was $9.58 Mil.

The historical rank and industry rank for InVivo Therapeutics Holdings's Equity-to-Asset or its related term are showing as below:

NVIVQ' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08   Med: 0.79   Max: 0.93
Current: 0.93

During the past 13 years, the highest Equity to Asset Ratio of InVivo Therapeutics Holdings was 0.93. The lowest was -0.08. And the median was 0.79.

NVIVQ's Equity-to-Asset is ranked better than
91.58% of 1567 companies
in the Biotechnology industry
Industry Median: 0.66 vs NVIVQ: 0.93

InVivo Therapeutics Holdings Equity-to-Asset Historical Data

The historical data trend for InVivo Therapeutics Holdings's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InVivo Therapeutics Holdings Equity-to-Asset Chart

InVivo Therapeutics Holdings Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.88 0.60 0.88 0.83 0.84

InVivo Therapeutics Holdings Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.84 0.86 0.87 0.93

Competitive Comparison of InVivo Therapeutics Holdings's Equity-to-Asset

For the Biotechnology subindustry, InVivo Therapeutics Holdings's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InVivo Therapeutics Holdings's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InVivo Therapeutics Holdings's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where InVivo Therapeutics Holdings's Equity-to-Asset falls into.



InVivo Therapeutics Holdings Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

InVivo Therapeutics Holdings's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )=Total Stockholders Equity/Total Assets
=15.746/18.822
=

InVivo Therapeutics Holdings's Equity to Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

Equity to Asset (Q: Sep. 2023 )=Total Stockholders Equity/Total Assets
=8.918/9.584
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InVivo Therapeutics Holdings  (OTCPK:NVIVQ) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


InVivo Therapeutics Holdings Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of InVivo Therapeutics Holdings's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Business Description

Traded in Other Exchanges
Address
One Kendall Square, Suite B14402, Building 1400 West, 4th Floor, Cambridge, MA, USA, 02139
InVivo Therapeutics Holdings Corp is a research and clinical stage biomaterials and biotechnology company. It focuses on the treatment of spinal cord injury. The company's product pipeline consists of Neuro spinal scaffold and Bioengineered neural trails. The firm has a clinical development program for acute spinal cord injury and a preclinical development program for chronic spinal cord injury.
Executives
Brice Foose 10 percent owner 236 SILENT MEADOW DRIVE, LAKE ST. LOUIS MO 63367
Daniel R Marshak director C/O CAMBREX CORP, ONE MEADOWLANDS PLZ, EAST RUTHERFORD NJ 07073
Christina Morrison director ARAMARK, 1101 MARKET STREET, PHILADELPHIA PA 19107
Richard M. Toselli director, officer: CEO and CMO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard Christopher officer: Chief Financial Officer C/O LUCID, INC., 50 METHODIST HILL DR, SUITE 1000, ROCHESTER NY 14623
C Ann Merrifield director
Bob Rosenthal director 20 NEWBURY ST, BOSTON MA 02116
Heather Hamel officer: Chief Legal Officer and GC ONE KENDALL SQUARE, BUILDING 1400 WEST, FLOOR 4, CAMBRIDGE MA 02139
Jeffrey Modestino officer: See Remarks C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14403, CAMBRIDGE MA 02139
Christopher Mcnulty officer: Chief Financial Officer C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Melanie Golarz officer: Interim CFO C/O INVIVO THERAPEUTICS HOLDINGS CORP., 1 KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Jeffrey S. Hatfield director 11080 ROSELLE STREET, SAN DIEGO CA 92121
Pamela J Stahl officer: Chief Commercial Officer ONE KENDALL SQUARE, SUITE B14402, CAMBRIDGE MA 02139
Richard John Roberts director ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Masuoka K. Lorianne officer: Chief Medical Officer C/O NEKTAR THERAPEUTICS, 201 INDUSTRIAL ROAD, SAN CARLOS CA 94070

InVivo Therapeutics Holdings (InVivo Therapeutics Holdings) Headlines